Compare IPCA Labs with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs FRESENIUS KABI ONCO. - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS FRESENIUS KABI ONCO. IPCA LABS/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 24.4 22.1 110.3% View Chart
P/BV x 8.7 3.1 280.4% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    IPCA LABS
Mar-19
FRESENIUS KABI ONCO.
Mar-13
IPCA LABS/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,042176 592.0%   
Low Rs59079 751.7%   
Sales per share (Unadj.) Rs298.637.7 792.4%  
Earnings per share (Unadj.) Rs35.05.1 687.2%  
Cash flow per share (Unadj.) Rs49.46.7 735.3%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs247.142.5 580.9%  
Shares outstanding (eoy) m126.35158.23 79.9%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.73.4 80.9%   
Avg P/E ratio x23.325.0 93.3%  
P/CF ratio (eoy) x16.518.9 87.2%  
Price / Book Value ratio x3.33.0 110.4%  
Dividend payout %8.60-   
Avg Mkt Cap Rs m103,10820,135 512.1%   
No. of employees `00013.41.2 1,166.8%   
Total wages/salary Rs m7,874703 1,119.7%   
Avg. sales/employee Rs Th2,807.05,176.2 54.2%   
Avg. wages/employee Rs Th585.8610.4 96.0%   
Avg. net profit/employee Rs Th329.0699.6 47.0%   
INCOME DATA
Net Sales Rs m37,7325,963 632.8%  
Other income Rs m57718 3,204.4%   
Total revenues Rs m38,3095,981 640.5%   
Gross profit Rs m6,9011,430 482.5%  
Depreciation Rs m1,824258 707.3%   
Interest Rs m189-26 -725.8%   
Profit before tax Rs m5,4651,216 449.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,042342 304.6%   
Profit after tax Rs m4,422806 548.7%  
Gross profit margin %18.324.0 76.3%  
Effective tax rate %19.128.1 67.8%   
Net profit margin %11.713.5 86.7%  
BALANCE SHEET DATA
Current assets Rs m23,7785,102 466.1%   
Current liabilities Rs m10,9752,385 460.1%   
Net working cap to sales %33.945.6 74.5%  
Current ratio x2.22.1 101.3%  
Inventory Days Days104150 69.2%  
Debtors Days Days66113 58.2%  
Net fixed assets Rs m20,3685,148 395.6%   
Share capital Rs m253158 159.7%   
"Free" reserves Rs m30,9716,556 472.4%   
Net worth Rs m31,2246,732 463.8%   
Long term debt Rs m1,409952 147.9%   
Total assets Rs m45,50710,388 438.1%  
Interest coverage x30.0-45.8 -65.4%   
Debt to equity ratio x00.1 31.9%  
Sales to assets ratio x0.80.6 144.4%   
Return on assets %10.17.5 135.0%  
Return on equity %14.212.0 118.3%  
Return on capital %17.314.6 118.6%  
Exports to sales %45.974.5 61.6%   
Imports to sales %16.624.8 67.0%   
Exports (fob) Rs m17,3084,441 389.8%   
Imports (cif) Rs m6,2661,477 424.2%   
Fx inflow Rs m17,3085,298 326.7%   
Fx outflow Rs m6,2661,772 353.6%   
Net fx Rs m11,0423,525 313.2%   
CASH FLOW
From Operations Rs m4,9231,274 386.4%  
From Investments Rs m-1,563-1,204 129.8%  
From Financial Activity Rs m-1,832-196 934.2%  
Net Cashflow Rs m1,528-126 -1,209.6%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 11.4 0.3 3,800.0%  
FIIs % 25.3 9.6 263.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 9.1 191.2%  
Shareholders   36,892 42,599 86.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   GLENMARK PHARMA  FULFORD INDIA  ORCHID PHARMA  AJANTA PHARMA  UNICHEM LAB  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Snap 4-Day Winning Streak; JSW Steel and Hindalco Among Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


May 11, 2021 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS